Company intelligence / Profile preview
Centessa Pharmaceuticals
Altrincham, Cheshire, United Kingdomcentessa.com ↗
- Ownership
- Public · CNTA
- Development stage
- Other
01
Overview
Centessa is a clinical-stage pharmaceutical company developing first-in-class and best-in-class medicines. Its most advanced program, ORX750, is an oral orexin receptor 2 agonist in Phase 1 trials for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Early data have been presented at major neurology conferences. The company also has early-stage programs targeting neurological/neurodegenerative/neuropsychiatric conditions and an immuno-oncology program using its proprietary LockBody® antibody engineering platform.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (orexin receptor agonists)Antibody-based therapeutics (LockBody® technology platform)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on Centessa Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centessa Pharmaceuticals.